EXCLUSIVE: Cincinnati medical practice reveals expansion plan
BrightView Health has opened an outpatient treatment facility in Chillicothe, and the Cincinnati-based medical practice intends to open similar addiction treatment centers in at least five more Ohio cities.
Founded in 2014 in Norwood and now based in Walnut Hills, BrightView has four Greater Cincinnati locations plus one in Dayton and the new center in Chillicothe.
BrightView, which cares for people battling drug or alcohol addictions, focuses on medication assisted treatment such as Suboxone,… (Source: bizjournals.com Health Care News Headlines)
Source: bizjournals.com Health Care News Headlines - November 14, 2018 Category: Health Management Authors: Barrett J. Brunsman Source Type: news
EXCLUSIVE: Cincinnati medical practice reveals expansion plan
BrightView Health has opened an outpatient treatment facility in Chillicothe, and the Cincinnati-based medical practice intends to open similar addiction treatment centers in at least five more Ohio cities.
Founded in 2014 in Norwood and now based in Walnut Hills, BrightView has four Greater Cincinnati locations plus one in Dayton and the new center in Chillicothe.
BrightView, which cares for people battling drug or alcohol addictions, focuses on medication assisted treatment such as Suboxone,… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - November 14, 2018 Category: Biotechnology Authors: Barrett J. Brunsman Source Type: news
Addiction Treatment Gap Is Driving A Black Market For Suboxone
This medicine to treat opioid addiction is hard to come by — only a fraction of doctors are approved to prescribe it. So some people trying to quit a heroin habit turn to a black market for help.(Image credit: Craig F. Walker/The Boston Globe/Getty Images) (Source: NPR Health and Science)
Source: NPR Health and Science - October 5, 2018 Category: Consumer Health News Authors: Jake Harper Source Type: news
Cassipa (Buprenorphine and Naloxone Sublingual Film) - new on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - September 19, 2018 Category: Drugs & Pharmacology Source Type: news
FDA Approves New Treatment for Opioid Dependence
MONDAY, Sept. 10, 2018 -- Cassipa (buprenorphine and naloxone), a film designed to be placed under the tongue, has been approved to treat opioid dependence, the U.S. Food and Drug Administration said in a news release.
Both buprenorphine and... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - September 10, 2018 Category: Pharmaceuticals Source Type: news
Cassipa Approved for Opioid Dependence
MONDAY, Sept. 10, 2018 -- Cassipa (buprenorphine and naloxone), a film designed to be placed under the tongue, has been approved to treat opioid dependence, the agency said in a news release.
Both buprenorphine and naloxone have been approved... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - September 10, 2018 Category: General Medicine Source Type: news
Teva wins FDA nod for sublingual film to treat opioid dependence
The FDA last week approved Teva Pharmaceuticals’ Cassipa buprenorphine and naloxone sublingual film as a maintenance treatment for opioid dependence.
There are a number of brand name and generic versions of buprenorphine and naloxone therapies that are delivered via a sublingual film. Teva’s product contains 16 milligrams buprenorphine and 4 milligrams of naloxone, bringing a new dosage strength to the market.
Get the full story at our sister site, Drug Delivery Business News.
The post Teva wins FDA nod for sublingual film to treat opioid dependence appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - September 10, 2018 Category: Medical Devices Authors: Sarah Faulkner Tags: Drug-Device Combinations Food & Drug Administration (FDA) Pharmaceuticals Regulatory/Compliance Wall Street Beat Teva Pharmaceuticals Source Type: news
FDA approves new dosage strength of buprenorphine and naloxone sublingual film as maintenance treatment for opioid dependence
FDA approved Cassipa (buprenorphine and naloxone) sublingual film (applied under the tongue) for the maintenance treatment of opioid dependence. (Source: Food and Drug Administration)
Source: Food and Drug Administration - September 7, 2018 Category: American Health Source Type: news
FDA Approves Cassipa (buprenorphine and naloxone) Sublingual Film as Maintenance Treatment for Opioid Dependence
September 7, 2018 -- The U.S. Food and Drug Administration today approved Cassipa (buprenorphine and naloxone) sublingual film (applied under the tongue) for the maintenance treatment of opioid dependence. This action provides a new dosage strength... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - September 7, 2018 Category: Drugs & Pharmacology Source Type: news
Buprenorphine/Naloxone Rx Fills Up With Medicaid Expansion
TUESDAY, Aug. 28, 2018 -- There was an increase in buprenorphine with naloxone fills in expansion versus nonexpansion counties after Medicaid expansion, according to a study published online Aug. 17 in JAMA Network Open.
Brendan Saloner, Ph.D., from... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - August 28, 2018 Category: Pharmaceuticals Source Type: news
Prescriptions for opioid use disorder treatment, opioid pain relievers after ACA Medicaid expansion
(JAMA Network) Medicaid expansion under the Affordable Care Act (ACA) was associated with an overall increase in people filling prescriptions for buprenorphine with naloxone, which is a treatment for opioid use disorder, as well as an increase in people filling prescriptions for opioid pain relievers (OPRs) paid for by Medicaid in a data analysis from five states. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - August 17, 2018 Category: International Medicine & Public Health Source Type: news
U.S. joins lawsuits against Indivior, Reckitt over drug Suboxone
The U.S. Justice Department has joined several whistleblower lawsuits against Indivior Plc and Reckitt Benckiser Group PLC, alleging that the drugmakers improperly marketed the opioid addiction treatment Suboxone. (Source: Reuters: Health)
Source: Reuters: Health - August 8, 2018 Category: Consumer Health News Tags: healthNews Source Type: news
U.S. Court Expedites Appeal to Re-Launch Generic Opioid Addiction Drug U.S. Court Expedites Appeal to Re-Launch Generic Opioid Addiction Drug
Indivior said on Monday a U.S. Court expedited a generic rival ' s appeal against a preliminary injunction that blocked the sale of a copycat version of the British drugmaker ' s blockbuster opioid addiction treatment, Suboxone Film (buprenorphine and naloxone).Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - July 31, 2018 Category: Consumer Health News Tags: Medscape Today News Source Type: news
The Satisfaction of Suboxone Treatment
(MedPage Today) -- It ' s become the most comprehensive, integrated thing that I do (Source: MedPage Today Psychiatry)
Source: MedPage Today Psychiatry - July 20, 2018 Category: Psychiatry Source Type: news
When an Iowa Family Doctor Takes On the Opioid Epidemic
Few primary care doctors are willing to do what Nicole Gastala has: endure the challenges of prescribing buprenorphine, a medication for opioid addiction. (Source: NYT Health)
Source: NYT Health - June 23, 2018 Category: Consumer Health News Authors: ABBY GOODNOUGH Tags: Buprenorphine (Drug) Opioids and Opiates Addiction (Psychology) Pain-Relieving Drugs Heroin Doctors Iowa Dr. Nicole Gastala suboxone Source Type: news
